Research Scientist

About Tabula

Tabula is building an AI-first therapeutics company.

We are starting with bacteriophages, natural predators of bacteria, and building the models and experimental systems needed to design better therapies for hard-to-treat infections. The immediate problem matters on its own. Antibiotic resistance is a large and growing global problem, and new approaches are badly needed. But we also think this is the beginning of something broader.

Most biotech companies are mostly biologists with a small computational team attached. We think that model is going to look dated. Our view is that drug and therapy discovery will become much more computational over time, and we are building Tabula around that belief from day one.

The core of our scientific work is the development of physics-based mathematical models of phage–bacteria interaction dynamics — how phages locate, bind to, infect, and replicate within bacterial targets at the population level — together with the large-scale numerical simulation of those models to identify and refine candidate therapies. To support that modeling, we run an in-house wet lab that generates the experimental data used to calibrate, test, and validate the underlying physical models.

Two things make this a particularly interesting problem. First, we own our data generation